IP Library Granted Patent US 7,674,798
Granted Patent B2
US 7,674,798 · App. 11/653,530 · Granted Mar 9, 2010

Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Assignee: Purdue Pharma L.P.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,674,798
App. No.
11/653,530
Granted
Mar 9, 2010
Kind
B2
Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Claims (17)

1. A packaged oxycodone hydrochloride composition comprising a pharmaceutically acceptable package containing at least 1 kg of an oxycodone hydrochloride active pharmaceutical ingredient having less than 25 ppm 14-hydroxycodeinone, wherein at least a portion of the 14-hydroxycodeinone is derived from 8α,14-dihydroxy-7,8-dihydrocodeinone during conversion of oxycodone free base to oxycodone hydrochloride.

2. The packaged oxycodone hydrochloride composition of claim 1 , wherein the 14-hydroxycodeinone is derived solely from 8α,14-dihydroxy-7,8-dihydrocodeinone.

3. The packaged oxycodone hydrochloride composition of claim 1 , wherein the oxycodone hydrochloride active pharmaceutical ingredient has less than 15 ppm 14-hydroxycodeinone.

4. The packaged oxycodone hydrochloride composition of claim 1 , wherein the oxycodone hydrochloride active pharmaceutical ingredient has less than 10 ppm 14-hydroxycodeinone.

5. The packaged oxycodone hydrochloride composition of claim 1 , wherein the oxycodone hydrochloride active pharmaceutical ingredient has a lower limit of 14-hydroxycodeinone of 0.25 ppm.

6. The packaged oxycodone hydrochloride composition of claim 1 , wherein the oxycodone hydrochloride active pharmaceutical ingredient has a lower limit of 14-hydroxycodeinone of 0.5 ppm.

7. The packaged oxycodone hydrochloride composition of claim 1 , wherein the oxycodone hydrochloride active pharmaceutical ingredient has a lower limit of 14-hydroxycodeinone of 1 ppm.

8. The packaged oxycodone hydrochloride composition of claim 1 , wherein the oxycodone hydrochloride active pharmaceutical ingredient has a lower limit of 14-hydroxycodeinone of 2 ppm.

9. The packaged oxycodone hydrochloride composition of claim 1 , wherein the oxycodone hydrochloride active pharmaceutical ingredient has a lower limit of 14-hydroxycodeinone of 5 ppm.

10. The packaged oxycodone composition of claim 1 , wherein the oxycodone hydrochloride active pharmaceutical ingredient has less than 5 ppm 14-hydroxycodeinone.

11. The packaged oxycodone hydrochloride composition of claim 1 , wherein the amount of the oxycodone hydrochloride active pharmaceutical ingredient in the pharmaceutically acceptable package is between about 10 kg and about 500 kg.

12. The packaged oxycodone hydrochloride composition of claim 1 , wherein the amount of the oxycodone hydrochloride active pharmaceutical ingredient in the pharmaceutically acceptable package is between about 20 kg and about 100 kg.

13. The packaged oxycodone hydrochloride composition of claim 1 , wherein the amount of the oxycodone hydrochloride active pharmaceutical ingredient in the pharmaceutically acceptable package is between about 20 kg and about 50 kg.

14. The packaged oxycodone hydrochloride composition of claim 1 , wherein the pharmaceutically acceptable package is a corrugated box container.

15. The packaged oxycodone hydrochloride composition of claim 1 , wherein the pharmaceutically acceptable package is a drum.

16. The packaged oxycodone hydrochloride composition of claim 1 , wherein the pharmaceutically acceptable package is a flexible intermediate bulk container.

17. The packaged oxycodone hydrochloride composition of claim 1 , comprising a liner between the pharmaceutically acceptable package and the oxycodone hydrochloride active pharmaceutical ingredient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 048936/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2010
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; P.F. LABORATORIES, INC. THE; PURDUE PHARMACEUTICALS L.P.; RHODES TECHNOLOGIES
Reel/Frame 024384/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2007
From: EURO-CELTIQUE, S.A.
To: PURDUE PHARMA L.P.
Reel/Frame 019939/0119 →
Continuity (8)
Continuation 1139189700 · Mar 29, 2006
Continuation 1109362600 · Mar 30, 2005
Provisional Application 6055749200 · Mar 30, 2004
Provisional Application 6060153400 · Aug 13, 2004
Provisional Application 6062007200 · Oct 18, 2004
Provisional Application 6064862500 · Jan 31, 2005
Provisional Application 6065177800 · Feb 10, 2005
Related Publication 20070117830A1 · May 24, 2007